3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with bromocriptine in 4 studies
| Studies (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Trials (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Recent Studies (post-2010) (3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide) | Studies (bromocriptine) | Trials (bromocriptine) | Recent Studies (post-2010) (bromocriptine) |
|---|---|---|---|---|---|
| 330 | 40 | 33 | 7,121 | 727 | 499 |
| Protein | Taxonomy | 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide (IC50) | bromocriptine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.532 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 2.4 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2.4996 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.015 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0016 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 2.281 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.035 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.52 | |
| D | Rattus norvegicus (Norway rat) | 0.0279 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0056 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 2.889 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.514 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.03 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.036 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.532 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0056 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0006 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0083 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.022 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0279 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Angelo, V; Di Fazio, P; Dicembrino, F; Liuzzi, A; Scarabino, T; Scillitani, A; Vettori, PP | 1 |
| Emrich, D; Hajak, G; Kögler, A; Munz, DL; Riemann, H; Rüther, E; Staedt, J; Stoppe, G | 1 |
| Hartman, NG; Lavigne, GJ; Lobbezoo, F; Montplaisir, JY; Soucy, JP | 1 |
| Ambrosio, G; Battista, C; Cascini, GL; Mansi, L; Panza, N; Rambaldi, PF; Schillirò, F | 1 |
2 trial(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and bromocriptine
| Article | Year |
|---|---|
Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).
Topics: Aged; Benzamides; Brain; Brain Chemistry; Bromocriptine; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Antagonists; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Myoclonus; Polysomnography; Pyrrolidines; Receptors, Dopamine D2; Sleep Wake Disorders; Tomography, Emission-Computed, Single-Photon | 1995 |
Effects of the D2 receptor agonist bromocriptine on sleep bruxism: report of two single-patient clinical trials.
Topics: Adult; Benzamides; Bromocriptine; Bruxism; Corpus Striatum; Cross-Over Studies; Dizziness; Dopamine Agonists; Dopamine Antagonists; Double-Blind Method; Electromyography; Female; Humans; Iodine Radioisotopes; Male; Masseter Muscle; Nausea; Patient Dropouts; Placebos; Polysomnography; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine; Sleep; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 1997 |
2 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and bromocriptine
| Article | Year |
|---|---|
In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas.
Topics: Adult; Benzamides; Brain; Bromocriptine; Female; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Pituitary Gland; Pituitary Neoplasms; Prolactin; Prolactinoma; Pyrrolidines; Receptors, Dopamine; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 1995 |
Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors.
Topics: Adult; Benzamides; Bromocriptine; Contrast Media; Growth Hormone; Humans; Indium Radioisotopes; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Octreotide; Pituitary Neoplasms; Prolactin; Pyrrolidines; Radionuclide Imaging; Tomography | 1999 |